Moderna Inc
$ 52.84
4.26%
14 Apr - close price
- Market Cap 20,099,021,000 USD
- Current Price $ 52.84
- High / Low $ 53.00 / 50.05
- Stock P/E N/A
- Book Value 21.95
- EPS -7.26
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.29 %
- 52 Week High 59.55
- 52 Week Low 22.28
About
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$45.15
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-11-06 | 2025-08-01 | 2025-04-30 | 2025-02-20 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -2.11 | -0.51 | -2.13 | -2.52 | -2.91 | 0.03 | -3.33 | -3.07 | 0.55 | -9.53 | -3.62 | 0.19 |
| Estimated EPS | -2.62 | -2.05 | -2.98 | -3.03 | -2.7599 | -1.9 | -3.38 | -3.58 | -0.97 | -1.93 | -4.04 | -1.77 |
| Surprise | 0.51 | 1.54 | 0.85 | 0.51 | -0.1501 | 1.93 | 0.05 | 0.51 | 1.52 | -7.6 | 0.42 | 1.96 |
| Surprise Percentage | 19.4656% | 75.122% | 28.5235% | 16.8317% | -5.4386% | 101.5789% | 1.4793% | 14.2458% | 156.701% | -393.7824% | 10.396% | 110.7345% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -2.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MRNA
2026-04-14 12:39:13
Cellectar Biosciences (NASDAQ: CLRB) has enrolled its first patient in a Phase 1b clinical trial for CLR 125, an Auger-emitting radioconjugate, aimed at treating relapsed or refractory triple-negative breast cancer (TNBC). The open-label study will evaluate three dose regimens to assess tumor uptake, safety, and preliminary efficacy, informing a recommended Phase 2 dose. This milestone advances Cellectar's strategy in developing targeted therapies for challenging cancers, with further updates expected throughout 2026.
2026-04-14 10:10:16
Novavax Inc. is strategically pivoting its vaccine development beyond COVID-19 to focus on a diversified pipeline targeting infectious diseases like flu, RSV, and combination vaccines. This shift leverages its protein-based vaccine platform and proprietary Matrix-M adjuvant, aiming for sustainable growth in the United States and English-speaking markets. The company's future success hinges on pipeline diversification, successful clinical readouts, strategic partnerships, and manufacturing resilience to compete with established players and mRNA rivals.
2026-04-14 06:38:03
Moderna is at a pivotal moment, aiming to diversify its revenue streams beyond COVID-19 vaccines into oncology, rare diseases, and latent virus vaccines using its mRNA technology. The company's pipeline of over 40 programs, including personalized cancer vaccines and respiratory vaccines, is central to its strategy for sustainable growth. While analysts see moderate upside driven by pipeline milestones, risks like patent expirations and competition remain, making execution on new indications and partnerships crucial for long-term success.
2026-04-14 06:08:08
Moderna is transitioning its mRNA platform beyond COVID-19 vaccines into oncology, rare diseases, and latent virus vaccines to diversify its revenue streams. This strategic shift aims to reduce reliance on single products and leverage the speed and flexibility of mRNA technology for a broad pipeline of over 40 programs. Investors are keen to see if this expansion into new markets and applications will generate sustainable growth and unlock new upside potential for the company.
2026-04-14 02:55:09
Moderna faces the critical challenge of demonstrating that its mRNA platform can deliver successful therapies beyond its COVID-19 vaccine. This pivot is essential for the company to sustain long-term value, as it expands its pipeline into areas like flu, RSV, cancer, and rare diseases. Investors are closely watching clinical trial data and the company's ability to maintain its competitive edge in a rapidly evolving biotech landscape.
2026-04-14 02:38:08
Moderna faces the crucial challenge of diversifying its mRNA platform beyond its highly successful COVID-19 vaccine. The company's future value hinges on its ability to develop and commercialize new therapies for respiratory viruses, oncology, and rare diseases. While its core mRNA technology offers agility and efficiency, successful execution in clinical trials and navigating competitive and regulatory landscapes will be key to long-term profitability for investors.
